Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jun 11;10:9510. doi: 10.1038/s41598-020-66490-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

The effects of topical application of ambrisentan or bosentan on clinical findings of IMQ-induced psoriasiform dermatitis. Shaved back skin and ears of B6 mice were topically treated with IMQ or control vehicle for 6 consecutive days. Topical ambrisentan or bosentan was administered from 4 days before IMQ application until the end of the study. (a,c) Pictures of mice were taken and the phenotypic symptoms of mouse skin were observed from day 0 to day 6. (b,d) Clinical scores for disease severity were calculated daily using a scoring system based on the clinical Psoriasis Area and Severity Index. Erythema, scales, and thickness were scored independently on a scale from 0 to 4: 0, none; 1, slight; 2, moderate; 3, marked; and 4, very marked. The cumulative score (erythema, scales, and thickness) served as a measure of the severity of inflammation (scale 0–12). Results are representative of similar results obtained in three independent experiments. Data are presented as mean ± SEM (n = 5 for each group). *P < 0.05, **P < 0.01 versus IMQ-treated group.